Objective: Cardiac surgery-associated acute kidney injury (CS-AKI) is associated with high mortality rates. This study aimed to determine the effects of perioperative dexmedetomidine (DEX) administration on CS-AKI in adult patients.
Design: A meta-analysis with trial sequential analysis of randomized controlled trials.
Setting: PubMed, EMBASE, Cochrane Library, and China National Knowledge Infrastructure databases were searched up to March 11, 2019 for relevant articles. The study protocol was registered at the International Prospective Register of Systematic Reviews (registration number: CRD42019128139).
Participants: Adult patients undergoing cardiac surgery.
Interventions: Dexmedetomidine compared with controls.
Measurements And Main Results: Nine randomized controlled trials with a total of 1,308 patients were included. Use of DEX significantly reduced the incidence of CS-AKI (risk ratio = 0.60, 95% confidence interval = 0.41-0.87, p = 0.008, I = 30%), without significant publication bias. The trial sequential analysis result suggested that there was enough evidence for this outcome. Sensitivity analysis confirmed the robustness of the result. The improvement of CS-AKI was primarily significant in preoperative and/or intraoperative administration of DEX with or without postoperative continuation, patients with age ≥60 years, and studies with low risk of bias. The subgroup analysis did not show statistical differences. Dexmedetomidine use also was associated with less prolonged ventilation and lower incidences of pulmonary complications and delirium postoperatively. The level of evidence was high for the incidence of CS-AKI on the Grading of Recommendations Assessment, Development and Evaluation profile.
Conclusion: Perioperative DEX administration provided protective effects against CS-AKI, especially when initiated before and during surgery in elderly patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1053/j.jvca.2019.09.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The ADESTE trial: A phase 2 study of enibarcimab, a monoclonal antibody targeting adrenomedullin, in acute heart failure.
ESC Heart Fail
January 2025
GREAT Network, Rome, Italy.
Aims: This study aimed to conduct a phase 2 proof-of-concept and safety study to evaluate the effect of ENIBARCIMAB (EN), a non-neutralizing humanized monoclonal antibody targeting the N-terminus of adrenomedullin (ADM), administered immediately after stabilization with standard of care (SoC) treatment, in patients hospitalized for acute heart failure (AHF).
Methods And Results: This prospective, open-label, controlled, interventional, multicenter, dose-escalation study was conducted at two cardiology sites in Indonesia. Patients were divided into two interventional groups sequentially receiving 0.
Advance care planning readiness, barriers, and facilitators among seriously ill Black older adults and their surrogates: A mixed methods study.
Palliat Support Care
January 2025
Department of Family Medicine, Warren Alpert Medical School of Brown University, Providence, RI, USA.
Objectives: Advance care planning (ACP) supports communication and medical decision-making and is best conceptualized as part of the care planning continuum. Black older adults have lower ACP engagement and poorer quality of care in serious illness. Surrogates are essential to effective ACP but are rarely integrated in care planning.
View Article and Find Full Text PDFEffect of Dexmedetomidine on the ED and ED of Sufentanil in Patient-Controlled Intravenous Analgesia After Cesarean Section: A Randomized, Controlled, Double-Blind Trial.
Drug Des Devel Ther
January 2025
Department of Anesthesiology, Affiliated Hospital of North Sichuan Medical College, Nanchong, People's Republic of China.
Purpose: To determine the effect of dexmedetomidine on the ED and ED of sufentanil in patient-controlled intravenous analgesia (PCIA) after cesarean section.
Patients And Methods: Parturients who underwent elective cesarean section (n = 80) were randomly assigned to either the sufentanil group (S group) or the dexmedetomidine-sufentanil combination group (DS group). Patients in the S group received a combination of sufentanil, 5 mg of tropisetron, and saline, whereas patients in the DS group were administered 1.
How pragmatic are randomised controlled trials evaluating minimally invasive surgery for oesophageal cancer? A methodological review of trial design using the Pragmatic-Explanatory Continuum Indicator Summary-2 (PRECIS-2) tool.
BMJ Open
December 2024
Centre for Surgical Research, University of Bristol, Bristol, UK.
Article Synopsis
- The study evaluates the validity and applicability of RCTs comparing minimally invasive and open surgeries for oesophageal cancer from January 2012 to June 2023.
- Only nine RCTs were found, with just one deemed pragmatic due to narrow eligibility criteria and single-centre designs limiting the generalizability of results.
- Recommendations include developing clearer guidelines for defining pragmatic trials to potentially enhance the applicability of future surgical RCTs in clinical practice.
Introduction: Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder among children and adolescents. The disorder negatively influences their academic performance and social relations, and their quality of life (QoL) is lower than that of peers without ADHD. The majority of children and adolescents with ADHD are treated with medication that potentially has an insufficient effect or frequently occurring adverse events.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!